Medtronic (MDT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
17 Aug, 2026Executive summary
Annual General Meeting scheduled for October 15, 2026, in Galway, Ireland, with voting available online and in person.
Shareholders are encouraged to review proxy materials and vote on key proposals by October 14, 2026.
Voting matters and shareholder proposals
Election of twelve director nominees to serve until the 2027 Annual General Meeting.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year 2027 and authorization for the Audit Committee to set remuneration.
Advisory approval of executive compensation (say-on-pay vote).
Renewal of Board authority to issue shares and to opt out of pre-emption rights under Irish law.
Authorization for the company and subsidiaries to make overseas market purchases of ordinary shares.
Board of directors and corporate governance
Twelve director nominees are presented for election, each to be voted on by separate resolution.
Latest events from Medtronic
- Shareholders will vote on key governance, compensation, and ESG matters amid strong FY26 results.MDT
Proxy filing - Innovation, digital transformation, and new growth drivers are fueling robust medtech expansion.MDT
2024 Wells Fargo Healthcare Conference - Record FY26 revenue growth and strong Q4 results set up for robust FY27 outlook.MDT
Q4 2026 - Q3 FY26 revenue up 8.7% to $9.0B, EPS beat guidance, and outlook remains strong.MDT
Q3 2026 - Q2 FY26 revenue and EPS beat guidance, with raised outlook and strong cardiovascular growth.MDT
Q2 2026 - A streamlined, long-lasting device addresses UUI with rapid adoption and broad market reach.MDT
Status Update - Aggressive investment in CAS, RDN, and Hugo robotics drives growth as diabetes spin advances.MDT
Morgan Stanley 23rd Annual Global Healthcare Conference - Q1 FY25 organic revenue rose 5.3% and EPS beat guidance, driven by innovation and segment growth.MDT
Q1 2025 - Strong Q4/FY25 growth, dividend hike, and Diabetes spin-off to drive margin and EPS gains.MDT
Q4 2025